UNSPSC 51202501: Leflunomide

This classification denotes a pyrimidine antagonist and dihydroorotate dehydrogenase inhibitor and angiogenesis activator inhibitor with the molecular formula C12H9F3N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) G162GK9U4W, chemically known as 4-isoxazolecarboxamide, 5-methyl-n-(4-(trifluoromethyl)phenyl but more generally known as leflunomide, which bears US NIH Compound Identifier 3899.

UNSPSC 51202501 Leflunomide, a Commodity code, nominally designates a specific immunosuppressant medication used in rheumatologic treatment, yet recent state and local procurement activity under this code shows minimal alignment with that narrow pharmaceutical scope. The recent opportunities tagged to this code span emergency medical supplies (naloxone and drug deactivation systems), generic multi-source pharmaceuticals and OTC products purchased through cooperative wholesalers, and exploratory market intelligence on direct-to-manufacturer prescription programs—none of which center on leflunomide or targeted immunosuppressant procurement. State and local health departments, county health services, fire rescue divisions, and cooperative purchasing alliances are the issuing bodies appearing in current activity, but the mismatch between the code's nominal scope and the work actually being solicited suggests either broad miscoding of pharmaceutical acquisitions under this commodity or minimal dedicated procurement activity for leflunomide itself.

Geographic activity centers on Florida (Seminole County's IFB60459723LAS for naloxone and drug deactivation systems, due July 26, 2023), Texas (HHS Commission's exploratory RFI HHS0017013 on direct-to-manufacturer prescriptions, response deadline April 3, 2026), Minnesota and multi-state coverage through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP's S1070000015802 RFP for generic pharmaceuticals and OTC products, due March 26, 2026), and Florida again (Tampa Fire Department's 26P00145 IFB for medical and first aid supplies, due March 13, 2026, with $700,000 estimated value and SLBE set-aside). The code shows little relevant recent activity focused specifically on leflunomide procurement; firms pursuing this code should verify whether their target customers are tagging leflunomide acquisitions under broader pharmaceutical family codes rather than this commodity designation.